<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36921564</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Investigation of liquid biopsy analytes in peripheral blood of individuals after SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>104519</StartPage><MedlinePgn>104519</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">104519</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2023.104519</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(23)00084-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Post-acute COVID-19 syndrome (PACS) is linked to severe organ damage. The identification and stratification of at-risk SARS-CoV-2 infected individuals is vital to providing appropriate care. This exploratory study looks for a potential liquid biopsy signal for PACS using both manual and machine learning approaches.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using a high definition single cell assay (HDSCA) workflow for liquid biopsy, we analysed 100 Post-COVID patients and 19 pre-pandemic normal donor (ND) controls. Within our patient cohort, 73 had received at least 1 dose of vaccination prior to SARS-CoV-2 infection. We stratified the COVID patients into 25 asymptomatic, 22 symptomatic COVID-19 but not suspected for PACS and 53 PACS suspected. All COVID-19 patients investigated in this study were diagnosed between April 2020 and January 2022 with a median 243 days (range 16-669) from diagnosis to their blood draw. We did a histopathological examination of rare events in the peripheral blood and used a machine learning model to evaluate predictors of PACS.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">The manual classification found rare cellular and acellular events consistent with features of endothelial cells and platelet structures in the PACS-suspected cohort. The three categories encompassing the hypothesised events were observed at a significantly higher incidence in the PACS-suspected cohort compared to the ND (p-value &lt; 0.05). The machine learning classifier performed well when separating the NDs from Post-COVID with an accuracy of 90.1%, but poorly when separating the patients suspected and not suspected of PACS with an accuracy of 58.7%.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Both the manual and the machine learning model found differences in the Post-COVID cohort and the NDs, suggesting the existence of a liquid biopsy signal after active SARS-CoV-2 infection. More research is needed to stratify PACS and its subsyndromes.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">This work was funded in whole or in part by Fulgent Genetics, Kathy and Richard Leventhal and Vassiliadis Research Fund. This work was also supported by the National Cancer InstituteU54CA260591.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Courcoubetis</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liljegren</LastName><ForeName>Emmett</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrera</LastName><ForeName>Ergueen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd Suite AC1072, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadri</LastName><ForeName>Maimoona</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghandehari</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Medical Center, Pulmonary Rehabilitation in the Women's Guild Lung Institute, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kazemian</LastName><ForeName>Elham</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd Suite AC1072, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reckamp</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd Suite AC1072, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merin</LastName><ForeName>Noah M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Division of Hematology and Cellular Therapy, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merchant</LastName><ForeName>Akil</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Hematology and Cellular Therapy, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA 90089, USA; Catherine &amp; Joseph Aresty Department of Urology, Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueiredo</LastName><ForeName>Jane C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd Suite AC1072, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shishido</LastName><ForeName>Stephanie N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhn</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA 90089, USA; Catherine &amp; Joseph Aresty Department of Urology, Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Department of Biomedical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles, CA 90089, USA; Department of Aerospace and Mechanical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles, CA 90089, USA; Department of Biological Sciences, Dornsife College of Letters, Arts, and Sciences, University of Southern California, Los Angeles, CA 90089, USA. Electronic address: pkuhn@usc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Liquid biopsy</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-COVID sequelae</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19 syndrome (PACS)</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Declaration of interests NN reports grants from NCI (1U54CA260591) during the conduct of the study. SG reports IBSA pharmaceutical grant and pending patent during the conduct of the study. KLR reports honoraria from AstraZeneca, Janssen and Lilly. AM reports grants from NCI (1U54CA260591) during the conduct of the study. JCF reports grants from NCI (1U54CA260591) during the conduct of the study. PK reports gift donations from Fulgent Genetics, Kathy and Richard Leventhal and Vassiliadis Research Fund. No other disclosures were reported by the other authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>15</Day><Hour>19</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36921564</ArticleId><ArticleId IdType="pmc">PMC10008671</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2023.104519</ArticleId><ArticleId IdType="pii">S2352-3964(23)00084-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C., Huang L., Wang Y., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Yao Q., Gu X., et al. 1-Year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398(10302):747&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M., Schommers P., Stecher M., et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Uzunova G., Pallanti S., Hollander E. Presentation and management of anxiety in individuals with acute symptomatic or asymptomatic COVID-19 infection, and in the post-COVID-19 recovery phase. Int J Psychiatry Clin Pract. 2021;25(2):115&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">33635172</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkova A., Kudryavtsev I., Starshinova A., et al. Post COVID-19 syndrome in patients with asymptomatic/mild form. Pathogens. 2021;10(11):1408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8620929</ArticleId><ArticleId IdType="pubmed">34832564</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevention CfDCa  COVID data tracker 2022. https://covid.cdc.gov/covid-data-tracker/#datatracker-home Available from:</Citation></Reference><Reference><Citation>Organization WH  WHO coronavirus (COVID-19) dashboard 2022. https://covid19.who.int/ Available from:</Citation></Reference><Reference><Citation>Moreno-P&#xe9;rez O., Merino E., Leon-Ramirez J.M., et al. Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J&#xa0;Infect. 2021;82(3):378&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel S.A.M., Olde Hartman T.C., Lucassen P., van Jaarsveld C.H.M. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract. 2022;39(1):159&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkodaymi M.S., Omrani O.A., Fawzy N.A., et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(5):657&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8812092</ArticleId><ArticleId IdType="pubmed">35124265</ArticleId></ArticleIdList></Reference><Reference><Citation>Lara Bull-Otterson P., Baca S., Sharon Saydah P., et al.   2022. Post&#x2013;COVID conditions among adult COVID-19 survivors aged 18&#x2013;64 and &#x2265;65 years &#x2014; United States, March 2020&#x2013;November 2021.https://www.cdc.gov/mmwr/volumes/71/wr/mm7121e1.htm#suggestedcitation [updated May 26, 2022. 71]. Available from:</Citation></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V., WHO Clinical Case Definition Working Group on Post-COVID-19 Condition A&#xa0;clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102&#x2013;e107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F., Ling S., Lui L.M.W., et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun. 2022;101:93&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacedonia D., Scioscia G., De Pace C.C., et al. How are we handling the post-COVID patients? The dance of uncertainties. Respiration. 2022;101(2):210&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8450839</ArticleId><ArticleId IdType="pubmed">34515235</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai S., Ruiz-Velasco C., Naghdloo A., et al. Identification of epithelial and mesenchymal circulating tumor cells in clonal lineage of an aggressive prostate cancer case. NPJ Precis Oncol. 2022;6(1):41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9213535</ArticleId><ArticleId IdType="pubmed">35729213</ArticleId></ArticleIdList></Reference><Reference><Citation>Bethel K., Luttgen M.S., Damani S., et al. Fluid phase biopsy for detection and characterization of circulating endothelial cells in myocardial infarction. Phys Biol. 2014;11(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4143170</ArticleId><ArticleId IdType="pubmed">24406475</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueiredo J.C., Merin N.M., Hamid O., et al. Longitudinal SARS-CoV-2 mRNA vaccine-induced humoral immune responses in patients with cancer. Cancer Res. 2021;81(24):6273&#x2013;6280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9060668</ArticleId><ArticleId IdType="pubmed">34759001</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueiredo J.C., Ihenacho U., Merin N.M., et al. SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment. Ann Oncol. 2022;33(1):109&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8527840</ArticleId><ArticleId IdType="pubmed">34687893</ArticleId></ArticleIdList></Reference><Reference><Citation>Bureau USC . 2020. Redistricting file&#x2013;PL 94-171.</Citation></Reference><Reference><Citation>Marrinucci D., Bethel K., Kolatkar A., et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol. 2012;9(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3387996</ArticleId><ArticleId IdType="pubmed">22306768</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai S., Matsumoto N., Storgard R., et al. Platelet-coated circulating tumor cells are a predictive biomarker in patients with metastatic castrate-resistant prostate cancer. Mol Cancer Res. 2021;19(12):2036&#x2013;2045.</Citation><ArticleIdList><ArticleId IdType="pubmed">34462330</ArticleId></ArticleIdList></Reference><Reference><Citation>Shishido S.N., Sayeed S., Courcoubetis G., et al. Characterization of cellular and acellular analytes from pre-cystectomy liquid biopsies in patients newly diagnosed with primary bladder cancer. Cancers (Basel) 2022;14(3):758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8833768</ArticleId><ArticleId IdType="pubmed">35159025</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann H.B., Whitney D.R. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat. 1947;18(1):50&#x2013;60.</Citation></Reference><Reference><Citation>Varga Z., Flammer A.J., Steiger P., et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Nizzoli M.E., Merati G., Tenore A., et al. Circulating endothelial cells in COVID-19. Am J Hematol. 2020;95(8):E187&#x2013;E188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300913</ArticleId><ArticleId IdType="pubmed">32491212</ArticleId></ArticleIdList></Reference><Reference><Citation>Guervilly C., Burtey S., Sabatier F., et al. Circulating endothelial cells as a marker of endothelial injury in severe COVID -19. J&#xa0;Infect Dis. 2020;222(11):1789&#x2013;1793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454721</ArticleId><ArticleId IdType="pubmed">32812049</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Y., Zhang J., Schiavon C.R., et al. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res. 2021;128(9):1323&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091897</ArticleId><ArticleId IdType="pubmed">33784827</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd8;stergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol Rep. 2021;9(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7849453</ArticleId><ArticleId IdType="pubmed">33523608</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikawa M., Kanno H., Zhou Y., et al. Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19. Nat Commun. 2021;12(1):7135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8660840</ArticleId><ArticleId IdType="pubmed">34887400</ArticleId></ArticleIdList></Reference><Reference><Citation>Venter C., Bezuidenhout J.A., Laubscher G.J., et al. Erythrocyte, platelet, serum ferritin, and P-selectin pathophysiology implicated in severe hypercoagulation and vascular complications in COVID-19. Int J Mol Sci. 2020;21(21):8234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7662625</ArticleId><ArticleId IdType="pubmed">33153161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M., Verleden S.E., Kuehnel M., et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N&#xa0;Engl J Med. 2020;383(2):120&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Vlok M., Venter C., et al. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Laubscher G.J., Pretorius E. A&#xa0;central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J. 2022;479(4):537&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Shishido S.N., Welter L., Rodriguez-Lee M., et al. Preanalytical variables for the genomic assessment of the cellular and acellular fractions of the liquid biopsy in a cohort of breast cancer patients. J&#xa0;Mol Diagn. 2020;22(3):319&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7103765</ArticleId><ArticleId IdType="pubmed">31978562</ArticleId></ArticleIdList></Reference><Reference><Citation>Welter L., Xu L., McKinley D., et al. Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient. Cold Spring Harb Mol Case Stud. 2020;6(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7784493</ArticleId><ArticleId IdType="pubmed">33203646</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerdtsson E., Pore M., Thiele J.A., et al. Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry. Converg Sci Phys Oncol. 2018;4(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6430142</ArticleId><ArticleId IdType="pubmed">30906572</ArticleId></ArticleIdList></Reference><Reference><Citation>Malihi P.D., Morikado M., Welter L., et al. Clonal diversity revealed by morphoproteomic and copy number profiles of single prostate cancer cells at diagnosis. Converg Sci Phys Oncol. 2018;4(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7363158</ArticleId><ArticleId IdType="pubmed">32670616</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerdtsson A.S., Setayesh S.M., Malihi P.D., et al. Large extracellular vesicle characterization and association with circulating tumor cells in metastatic castrate resistant prostate cancer. Cancers (Basel) 2021;13(5):1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7958848</ArticleId><ArticleId IdType="pubmed">33801459</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>